Developing a Humanized Mouse Model with Human Liver Cells and Immune Cells
Transcript
Begin with an anesthetized, immunodeficient mouse that lacks various immune cells.
This transgenic mouse is pretreated with an antiviral and a chemotherapeutic agent. The antiviral agent exclusively interacts with viral proteins present in transgenic liver cells, promoting their elimination.
Meanwhile, the chemotherapeutic agent eliminates the actively dividing stem cells in the bone marrow, creating a niche for immune cell generation.
Dissect the mouse and expose the spleen.
Take the cell suspension of human liver cells and hematopoietic stem progenitor cells or HSPCs and inject them into the lower pole of the spleen.
Ligate the spleen above the injection site to restrict cells to the lower pole and facilitate their entry into the mouse circulation.
Close the incision.
The injected liver cells reach the liver tissue and establish human liver cells in the mouse model.
In the bone marrow, migrated HSPCs differentiate into various human immune cells.
This develops a dual humanized mouse model with human liver cells and immune cells.
